Continuous Bioprocessing Patents: Who Leads, Where the Gaps Are 2026
Continuous Upstream-Downstream Integration Patents: Leaders, Trends and White Space
68.4% concentration. The top 5 of 39 ranked assignees hold 128 of the 187 records in scope — a field with a small set of entrenched filers and a long tail below them. Filings were at zero in 2017, rose to a peak of 17 in 2018, and by the last complete year on record (2024) had fallen to 7 — down from 11 in 2021, a 36% drop over that three-year span. The 2025-2026 counts will keep rising as publication catches up with filing, so treat the most recent one to two years as incomplete rather than as a real slowdown.
- 1BAYER HEALTHCARE LLC54
- 2CHINA PETROLEUM & CHEMICAL CORP25
- 3EMD MILLIPORE CORP20
- 4CHEVRON PHILLIPS CHEMICAL COMPANY LP20
- 5TATA CONSULTANCY SERVICES LTD9
See the full continuous upstream downstream integration analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about this landscape
What counts as continuous upstream-downstream integration in patent terms?
It refers to patents that treat cell culture/fermentation (upstream) and purification/capture (downstream) as one connected process rather than separate batch stages. The claims typically cover process control strategy across the join, residence time distribution through connected equipment, material diversion during transitions, or the physical flow-path integration and footprint reduction that make a continuous line possible. This dataset uses those specific terms to isolate 187 records that go beyond simply combining two batch unit operations.
Who are the leading patent holders in continuous bioprocessing integration?
The field is concentrated: the top 5 of 39 ranked assignees account for 68.4% of the 187 records in scope, and the top 10 reach 86.1%. The single leading assignee holds 54 records on its own, far ahead of the fifth-place holder’s 9, so most of the claim territory sits with a handful of established life-sciences equipment and pharma companies rather than being spread evenly across the field.
Is patent filing in this space growing or slowing down?
Filing peaked in 2018 at 17 records and has since stepped down; from 2021 to 2024, the last year with largely complete publication, filings fell from 11 to 7, a 36% decline. That said, publication typically lags filing by around 18 months, so the 2025-2026 counts in this dataset are still incomplete and should not be read as proof of a continuing decline until later data confirms it.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Continuous Upstream Downstream Integration covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.